Pharmaceutical

AstraZeneca files patent for improved production of aav vectors using specific plasmid sequence

Discover how AstraZeneca's new patent revolutionizes AAV vector production with specific polynucleotide sequences, excluding cap genes.

Mar 13, 2024 - 00:00
Discover how AstraZeneca's new patent revolutionizes AAV vector production with specific polynucleotide sequences, excluding cap genes.
Read the original article

Tags:

Previous Article

Zealand Pharma files patent for pharmaceutical composition with GLP-1/GLP-2 dual...

Next Article

Dr. Reddy’s Laboratories files patent for 6-substituted pyridazine compounds for...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Biogen to slash 1,000 more jobs; key House panel proposes lowering Medicare out-of-pocket drug costs

STAT+: Pharmalittle: Biogen to slash 1,000 more jobs; k...

Jul 26, 2023

STAT+: Mass General Brigham CEO opens up about the Dana-Farber Cancer Institute split

STAT+: Mass General Brigham CEO opens up about the Dana...

Sep 30, 2023

STAT+: Dana-Farber cancer researchers moving to retract one paper, correct others in broad investigation of manipulated data

STAT+: Dana-Farber cancer researchers moving to retract...

Jan 20, 2024